News & Events

COVID-19 Letter from our CEO Tom Galati

We’re ready to do our part to take on COVID-19

Let’s work together to combat COVID-19

Accelerating the development of vaccines and therapies to combat the COVID-19 pandemic is an urgent priority across the medical research and healthcare community. At StageBio, we recognize the role preclinical histopathology and animal models play in finding solutions for COVID-19.   We stand ready to contribute our resources and expertise to help address this worldwide threat  to human health.

Our team has experience working with animal models of other highly infectious viruses—including SARS-CoV, Influenza strains such as H5N1 and H1N1, Respiratory Syncytial Virus, and Measles Virus—to support the development of vaccines, prophylactic measures, and post-exposure therapeutics. Our robust resources include two fully functional investigational laboratories with the capability to perform IHC, IF, and other molecular pathology techniques.
Learn more about our capabilities relating to the coronavirus.

Mitigating the impact of coronavirus 2 and COVID-19 on our society requires the focused commitment of us all. At StageBio, we are fully mobilized in histology laboratories and our pathologists are ready to do their part to accelerate the development of life-saving vaccines and therapies.

Whether you represent a contract research organization (CRO), pharmaceutical R&D department, academic institution, government agency, or other organization taking on the COVID-19 challenge, let’s explore how we can partner to accelerate your research and help save lives.

Together, we can make a positive difference for people worldwide. Let’s get started.

Sincerely,

Tom Galati
CEO

For further information contact:
Sam Jeffrey
Chief of Staff
info@stagebio.com

 

Back to Index

Learn more about StageBio’s COVID-19 response